

1 **Impact of Proximal Tubule-Specific Deletion of Dipeptidyl Peptidase 4 on Blood**
2 **Pressure, Renal Sodium Handling, and NHE3 Phosphorylation**

3

4 Flavia L. Martins PhD^{1,2*}, Joao Carlos Ribeiro-Silva PhD^{3*}, Erika Fernandes de Jesus¹,
5 Ravi Nistala MD^{2§}, and Adriana C. C. Girardi, PhD^{1§}

6

7 ¹Laboratorio de Genética e Cardiologia Molecular, Faculdade de Medicina, Instituto do
8 Coração (InCor), Hospital das Clínicas HCFMUSP, Universidade de Sao Paulo, Sao
9 Paulo, SP, Brazil; ²Division of Nephrology, Department of Medicine, University of
10 Missouri School of Medicine, Columbia, MO, USA; ³State University of New York
11 (SUNY) Upstate Medical University, Syracuse, NY, USA.

12

13 *These authors contributed equally to this work and should both be regarded as first
14 authors.

15

16 **Short title: Proximal Tubule *Dpp4* Deletion and Natriuresis**

17 Word count: 5580

18 Figures: 6

19

20 **§Correspondence**

21 Adriana C. C. Girardi, PhD (adriana.girardi@incor.usp.br)

22 Laboratório de Genética e Cardiologia Molecular, Instituto do Coração (InCor), Hospital
23 das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo. Avenida
24 Dr. Enéas de Carvalho Aguiar, 44 - Bloco II 10° andar. 05403-900 – São Paulo, Brazil.
25 Phone: +55-11-2661-5929

26

27 Ravi Nistala, MD (nistalar@health.missouri.edu)

28 Division of Nephrology, Department of Internal Medicine, University of Missouri-
29 Columbia School of Medicine. 5 Hospital Drive, Columbia, MO 65212, USA.

30 Phone: +1-573-884-4820

31 **ABSTRACT**

32

33 Dipeptidyl peptidase 4 (DPP4) is a transmembrane serine exopeptidase abundantly
34 expressed in the kidneys, predominantly in the proximal tubule (PT); however, its non-
35 enzymatic functions in this nephron segment remain poorly understood. While DPP4
36 physically associates with the Na⁺/H⁺ exchanger isoform 3 (NHE3) and its inhibitors
37 exert natriuretic effects, the DPP4 role in blood pressure (BP) regulation remains
38 controversial. This study investigated the effects of PT-specific *Dpp4* deletion (*Dpp4*^{ΔPT})
39 and global *Dpp4* deletion (*Dpp4*^{-/-}) on systolic blood pressure (SBP), natriuresis, and
40 NHE3 regulation under baseline and angiotensin II (Ang II)-stimulated conditions in both
41 male and female mice. Global and PT-specific *Dpp4* deletion increased diuretic and
42 natriuretic responses to acute saline loading, correlating with enhanced phosphorylation
43 of NHE3 at serine 552 (pS552-NHE3). However, baseline SBP remained unchanged.
44 Ang II stimulation increased DPP4 activity in control mice, with a greater effect in males
45 than in females, reflecting sex-dependent regulation of renal DPP4. In *Dpp4*^{ΔPT} mice,
46 residual kidney DPP4 was unresponsive to Ang II, indicating that PT DPP4, rather than
47 DPP4 in other nephron segments, is regulated by Ang II. Ang II administration
48 increased SBP in all groups; however, the pressor response was significantly
49 attenuated in both *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice, coinciding with sustained elevated levels
50 of pS552-NHE3. Collectively, these findings demonstrate that PT DPP4 modulates
51 NHE3 activity through mechanisms that prevent the accumulation of pS552-NHE3,
52 exerting an anti-natriuretic effect. In the absence of DPP4, these mechanisms are
53 disrupted, reducing Ang II sensitivity and maintaining high pS552-NHE3 levels,
54 underscoring the role of DPP4 in PT signaling and function.

55

56

57 Keywords: dipeptidyl peptidase 4, NHE3, proximal tubule, natriuresis, blood pressure,
58 angiotensin II

59

60 **NON-STANDARD ABBREVIATIONS AND ACRONYMS**

61	Ang II	Angiotensin II
62	AT1R	Angiotensin II type 1 receptor
63	BP	Blood pressure
64	DPP4	Dipeptidyl peptidase 4
65	DPP4is	Dipeptidyl peptidase 4 inhibitors
66	GLP-1	Glucagon-like peptide-1
67	NHE3	Na ⁺ /H ⁺ exchanger isoform 3
68	PT	Proximal tubule
69	RAS	Renin-angiotensin system
70	SHR	Spontaneously hypertensive rat

71 INTRODUCTION

72 Dipeptidyl peptidase 4 (DPP4/CD26) is a widely expressed serine protease found
73 in epithelial and non-epithelial cells across various tissues, with particularly high levels
74 in the kidney¹. In renal tissue, DPP4 is localized in the glomeruli and the proximal tubule
75 (PT), where it is a major component of the microvilli brush border²⁻⁴. In addition to its
76 enzymatic activity, DPP4 is involved in a variety of biochemical pathways and physically
77 associates with multiple proteins, including adenosine deaminase⁵, caveolin⁶,
78 components of the extracellular matrix^{7,8}, and the sodium-hydrogen exchanger 3
79 (NHE3)^{3,9}.

80 In the PT, NHE3 mediates approximately 70% of filtered sodium reabsorption,
81 playing a crucial role in extracellular volume homeostasis and blood pressure (BP)
82 control¹⁰⁻¹². Mice with PT-specific deletion of *Nhe3* display lower BP, enhanced
83 pressure-natriuresis, and attenuated hypertensive responses to chronic angiotensin II
84 (Ang II) infusion compared to wild-type controls^{12,13}. Notably, studies have shown that
85 following the onset of hypertension, PT NHE3-mediated sodium reabsorption declines¹⁴⁻
86 ¹⁶, thereby limiting further BP increases^{17,18}. This reduction in NHE3 activity is thought to
87 result from increased phosphorylation at serine 552, along with a redistribution of NHE3
88 from the body to the base of the PT microvilli^{14,19}.

89 Previous work demonstrates that DPP4 inhibitors (DPP4is) downregulate PT
90 NHE3 activity, leading to natriuresis²⁰⁻²². However, despite their natriuretic properties,
91 the impact of DPP4is on BP remains inconclusive. While some studies reported BP
92 reductions in individuals with mild hypertension²³, chronic kidney disease models²⁴, and
93 pre-hypertensive spontaneously hypertensive rats (SHRs)²⁵, findings in adult

94 hypertensive animals have been mixed, with outcomes ranging from BP reduction to no
95 change or even BP increases²⁵⁻²⁷.

96 Given the limited understanding of the physiological role of PT DPP4 and the
97 variable BP responses to DPP4i across different contexts, we generated mice with PT-
98 specific deletion of *Dpp4* and assessed BP, the response to acute saline loading, and
99 phosphorylation of renal NHE3 at serine 552 under both baseline and Ang II-induced
100 BP elevation conditions. To further clarify the specific contribution of PT DPP4, we
101 conducted parallel experiments in global *Dpp4* knockout mice. Additionally, we
102 examined potential sex differences in these regulatory mechanisms.

103

104 **METHODS**

105 The data supporting this study's findings are available from the corresponding
106 authors upon request.

107 An expanded Methods section is available in the Online-Only Data Supplement.

108

109 **Experimental animals**

110 All animal procedures were approved by the Institutional Animal Care and Use
111 Committee of the University of Missouri and the University of São Paulo Medical School
112 in compliance with the National Institutes of Health Guide for the Care and Use of
113 Laboratory Animals. Mice were housed under a 12-hour light/dark cycle in standard
114 rodent cages with free access to standard chow and tap water. Homozygous PT-*Dpp4*
115 knockout mice were generated by crossing *Dpp4*-floxed (*Dpp4*^{F1/F1}) (Model 10935,
116 Taconic Biosciences, Rensselaer, NY)²⁸ female mice with male *Sgt12*-Cre mice²⁹ (kindly

117 provided by Dr. Jia L Zhuo, University of Mississippi Medical Center, Jackson, MS,
118 USA). Genotyping was conducted following established protocols (Figure S1 and Table
119 S1). Twelve-week-old mice, including PT-*Dpp4* knockout mice (*Dpp4*^{ΔPT}, n=22), *Sglt2*-
120 *Cre*^{negative} *Dpp4*^{F1/F1} littermate controls (CTRL, n=22), global *Dpp4* knockout mice (*Dpp4*^{-/-},
121 n=32), and wild-type mice (n=33) were used in this study. Systolic blood pressure (SBP)
122 was measured in acclimated mice using plethysmography, and a saline challenge
123 protocol was conducted by administering an intraperitoneal injection of warmed (37°C)
124 saline (0.9% NaCl) equivalent to 10% of their body weight (v/w)³⁰. Immediately after,
125 they were placed in metabolic cages (Tecniplast, Buguggiate, VA, Italy) for a 5-hour
126 urine collection. Urinary volume and sodium excretion were expressed as the
127 percentage of injected fluid and sodium load. To assess the pressor response to Ang II,
128 SBP was recorded 15 minutes before (baseline) and 45 minutes after intraperitoneal
129 Ang II injection (60 μg/kg) (Figure S2). Saline-injected animals served as controls.
130 Kidneys were collected one-hour post-injection, coinciding with peak kidney DPP4
131 activity and pS552-NHE3 levels (Figure S3). At this time, mice were sedated (4%
132 isoflurane) and subsequently euthanized by cervical dislocation.

133

134 **Statistical analysis**

135 Data are presented as mean ± standard error of the mean (SEM). The sample
136 size (n) for each analysis is indicated by individual points in the scatter-dot plots.
137 Comparisons were made using two-way ANOVA followed by Tukey's post hoc test, with
138 statistical significance set at $P < 0.05$.

139

140 RESULTS

141 Phenotypic characterization of PT-specific *Dpp4* deletion in mice

142 Mice with PT-specific deletion of *Dpp4* (*Dpp4*^{ΔPT}) showed a ~35% reduction in
143 kidney DPP4 in males and a ~45% reduction in females compared to CTRL mice
144 (Figure 1A). Immunostaining of kidney sections for DPP4 and SGLT2, a PT marker,
145 confirmed that this reduction was specific to the PT. In CTRL mice, DPP4 is evidenced
146 in both the PT, where it colocalizes with SGLT2, and the glomeruli. In contrast, *Dpp4*^{ΔPT}
147 mice showed DPP4 staining exclusively in the glomeruli (Figure 1C). Similarly, kidney
148 DPP4 activity decreased by approximately 30% in *Dpp4*^{ΔPT} males and 40% in *Dpp4*^{ΔPT}
149 females compared to CTRL mice (Figure 1E). Mice with global *Dpp4* deletion (*Dpp4*^{-/-})
150 showed absence of DPP4 protein (Figure 1B), staining (Figure 1D), and activity (Figure
151 1F). Consistent with previous findings³¹, kidney DPP4 exhibited sexual dimorphism, with
152 higher abundance and activity in females than in males (Figure 1).

153 SBP assessment by plethysmography showed no baseline differences between
154 *Dpp4*^{ΔPT} and CTRL (Figure 2A) or between *Dpp4*^{-/-} and WT mice (Figure 2B), with
155 preserved sex-based BP differences, as female *Dpp4*^{ΔPT} exhibited lower BP than males.
156 Despite comparable SBP, both *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice exhibited more rapid acute
157 diuretic (Figure 2C-D) and natriuretic (Figure 2E-F) responses to a saline challenge
158 compared to littermate controls. Consistent with previous evidence³¹, acute diuretic
159 (Figure 2C-D) and natriuretic (Figure 2E-F) responses to a saline load were faster in
160 female mice than in males. Interestingly, mice with *Dpp4* deletion (both PT-specific and
161 global) exhibited comparable fluid and salt excretion percentages between males and
162 females (Figure 2C-D).

163 The more rapid diuretic and natriuretic responses to a saline challenge in
164 *Dpp4*^{ΔPT} mice suggest reduced sodium and fluid reabsorption in the PT, a function
165 primarily mediated by NHE3. Given that some studies have linked DPP4 inhibition to
166 downregulation of NHE3 activity and increased pS552-NHE3 levels³², we investigated
167 kidney pS552-NHE3 levels in our experimental models. CTRL females had higher renal
168 pS552-NHE3 levels than CTRL males, as previously reported³¹. Notably, pS552-NHE3
169 levels were approximately twofold higher in *Dpp4*^{ΔPT} mice (Figure 3A) and fourfold
170 higher in *Dpp4*^{-/-} mice, in both males and females, compared to their respective controls
171 (Figure 3B). The greater increase in pS552-NHE3 in *Dpp4*^{-/-} mice compared to *Dpp4*^{ΔPT}
172 mice may be partly due to background differences between CTRL (*Dpp4*^{F1/F1}) and WT
173 mice, as CTRL mice exhibited higher renal pS552-NHE3 levels than WT (Figure S4).
174 Consequently, the difference between *Dpp4*^{ΔPT} and *Dpp4*^{F1/F1} was less pronounced than
175 between *Dpp4*^{-/-} and WT.

176 The sexual dimorphism in pS552-NHE3 was preserved in the absence of DPP4,
177 being predominantly higher in females than male counterparts (Figure 3). The total
178 NHE3 abundance remained unchanged across all experimental groups (Figure S5),
179 consistent with previous findings showing that DPP4 influences NHE3 through
180 posttranslational mechanisms rather than altering its abundance^{22,32}.

181

182 **Ang II-induced BP elevation is similarly attenuated in both *Dpp4*^{ΔPT} and *Dpp4*^{-/-}** 183 **mice compared to controls**

184 Based on our observations that the absence of DPP4 enhanced the acute
185 diuretic and natriuretic responses, along with elevated pS552-NHE3 in the kidneys of

186 *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice, we hypothesized that mice lacking *Dpp4* might exhibit an
187 enhanced pressure-natriuresis response, thereby attenuating BP increases. We then
188 investigated whether an acute injection of a pressor dose of Ang II would raise BP to a
189 lesser extent in *Dpp4*^{ΔPT} mice than in CTRL (Figures S2 and S3). Additionally, we
190 examined whether *Dpp4*^{-/-} would have a greater or similar effect on attenuating Ang II-
191 induced BP increases compared to PT-specific deletion. As seen in Figure 4A-B, CTRL
192 mice treated with a supraphysiological concentration of Ang II (60 μg/kg) showed a
193 higher DPP4 activity, with an increase of approximately 50% in males and 30% in
194 females compared to saline. Interestingly, residual kidney DPP4 activity in *Dpp4*^{ΔPT}
195 mice remained unchanged in response to Ang II (Figure 4), suggesting that Ang II
196 specifically regulates PT DPP4 activity. Total DPP4 levels remained unchanged under
197 both saline and Ang II conditions in wild-type mice (Figure S6).

198 SBP was measured before and after Ang II injection (Figure S7), and the change
199 in BP (Δ SBP) was calculated. Ang II administration increased SBP across all
200 experimental groups (Figure S7, right panels). As seen in Figure 5, the pressor
201 response (Δ SBP = Post-Ang II SBP – Baseline BP) was significantly attenuated in
202 *Dpp4*^{ΔPT} compared to CTRL males: 17 ± 1 vs. 29 ± 1 mmHg ($P < 0.0001$) and females:
203 20 ± 1 vs. 28 ± 2 mmHg ($P < 0.002$). Similarly, Δ SBP was also lower in *Dpp4*^{-/-} mice
204 compared to WT males: 24 ± 1 vs. 34 ± 2 mmHg ($P < 0.0001$) and females: 25 ± 2 vs.
205 32 ± 3 mmHg ($P < 0.03$), demonstrating that PT DPP4 contributes to the pressor
206 response to Ang II independently of sex.

207 Next, we aimed to determine whether the reduced pressor response to Ang II
208 was associated with further upregulation of pS552-NHE3 in *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice.

209 In CTRL mice, Ang II administration significantly increased pS552-NHE3 levels (males:
210 Ang II $229 \pm 8\%$ vs. saline $100 \pm 5\%$, $P < 0.0002$; females: Ang II $180 \pm 14\%$ vs. saline
211 $100 \pm 3\%$, $P < 0.0002$). In *Dpp4*^{ΔPT} mice, however, Ang II further increased pS552-
212 NHE3 by 95% in males and 61% in females (Figure 6A-B). Similar findings were
213 observed in *Dpp4*^{-/-} mice. Ang II increased WT pS552-NHE3 levels (males: Ang II $472 \pm$
214 68 vs. saline $100 \pm 5\%$, $P < 0.0005$; females: Ang II 359 ± 32 vs. saline $100 \pm 6\%$, $P <$
215 0.0001). In contrast, Ang II injection in *Dpp4*^{-/-} mice resulted in a greater increase in
216 pS552-NHE3 (176% in males and 104% in females) (Figures 6C and 6D). Total NHE3
217 levels remained constant across all experimental conditions (Figure S8). Collectively,
218 these findings suggest that the absence of DPP4 enhances NHE3 S552
219 phosphorylation, thereby attenuating the pressor response to Ang II

220

221 **DISCUSSION**

222 This study is the first to examine the impact of PT-specific *Dpp4* deletion on
223 natriuresis, renal pS552-NHE3 levels, and BP. Our findings demonstrate that both PT-
224 specific and global *Dpp4* knockout models similarly enhance the natriuretic and diuretic
225 responses to saline load in mice. These findings highlight DPP4's role in mechanisms
226 regulating salt reabsorption, likely within the PT. Furthermore, both *Dpp4*^{ΔPT} and *Dpp4*^{-/-}
227 mice exhibit upregulation of renal pS552-NHE3 levels, suggesting a baseline reduction
228 in PT NHE3 activity. The comparable reduction in the Ang II-induced BP rise observed
229 in both knockout models, relative to littermate controls, suggests that PT-specific *Dpp4*
230 deletion uniquely counteracts the acute pressor effect of Ang II, likely by enhancing the
231 pressure-natriuresis response.

232 We previously demonstrated that DPP4 preferentially interacts with NHE3 in the
233 body of the microvilli³, where NHE3 is active^{33,34}, while phosphorylated NHE3 at serine
234 552 (pS552-NHE3) localizes to the base of the brush-border microvilli³⁵, where NHE3 is
235 inactive^{33,34}. In this study, we found that pS552-NHE3 levels are significantly higher in
236 *Dpp4* knockout mice than controls, supporting the notion that baseline NHE3 activity is
237 reduced in the absence of DPP4. These findings raised two key questions: (i) Why does
238 *Dpp4* deletion enhance NHE3 phosphorylation? (ii) Is DPP4 involved in regulating
239 NHE3's subcellular distribution? As serine 552 (S552) is a consensus site for protein
240 kinase A (PKA)-mediated inhibition of NHE3³⁶, one plausible mechanism for increased
241 pS552-NHE3 levels following *Dpp4* deletion is the enhanced bioavailability of DPP4
242 substrates such as glucagon-like peptide-1 (GLP-1), which activates Gs-coupled
243 receptors³⁷. GLP-1 is known to promote natriuresis, at least in part, through PKA-
244 dependent inhibition of NHE3 via pS552 phosphorylation. However, the natriuretic
245 effects of DPP4is are also observed in mice lacking the GLP-1R²¹ and in isolated PT
246 cells²⁰ that do not produce GLP-1. These findings suggest that DPP4's regulation of
247 NHE3 activity and phosphorylation may also occur independently of GLP-1, potentially
248 involving alternative signaling pathways or protein interactions. In this regard, we have
249 previously demonstrated that the interaction between DPP4 and NHE3 is indirect and
250 requires intermediary proteins³⁸. Among these, motor proteins involved in NHE3's
251 subcellular distribution across brush-border microdomains are likely candidates³⁹.
252 Ongoing studies aim to clarify these mechanisms and identify additional mediators of
253 the DPP4-NHE3 interaction.

254 Our data show that female mice exhibit higher DPP4 expression and enzymatic

255 activity, consistent with findings in rats and humans^{31,40,41}. Despite DPP4's role in
256 stimulating NHE3 activity, females paradoxically have higher pS552-NHE3 levels and a
257 faster natriuretic response to saline challenge than males. This discrepancy could be
258 explained by a lower expression of intermediary proteins mediating the DPP4-NHE3
259 interaction in females, which may reduce NHE3 activation despite elevated DPP4
260 levels.

261 Despite elevated levels of renal pS552-NHE3 in both *Dpp4* knockout models,
262 baseline SBP remained unchanged compared to controls, possibly due to
263 compensatory increases in the activity of apical sodium transporters and/or channels in
264 the distal nephron. A potential candidate for this compensation is the sodium-chloride
265 cotransporter (NCC), which we have previously shown to be upregulated in the distal
266 convoluted tubule (DCT) to counteract the inhibition of PT NHE3 by sodium-glucose
267 cotransporter-2 inhibitors (SGLT2i) in normotensive rats³⁰. In agreement, we observed
268 that NCC phosphorylated at threonine 53 (pNCC), the active form of NCC⁴², is
269 upregulated in both PT-specific and global *Dpp4* knockout mice (see Supplemental
270 Figure S9). This upregulation likely reflects an adaptive response by the DCT, where
271 increased sodium delivery from PT inhibition stimulates sodium reabsorption capacity in
272 the DCT⁴³.

273 Our findings also demonstrate that the Ang II-mediated BP rise was significantly
274 attenuated in both *Dpp4*^{ΔPT} and *Dpp4*^{-/-}. This attenuation was accompanied by further
275 upregulation of kidney NHE3 phosphorylation at serine 552. Elevated kidney pS552-
276 NHE3 and NHE3 redistribution within microvillar microdomains, resulting in reduced
277 NHE3 activity, have been associated with pressure-natriuresis in several hypertension

278 models^{14,17,44,45}. In SHR, for instance, PT NHE3-mediated sodium reabsorption is
279 higher before hypertension onset but subsequently declines compared to normotensive
280 rats¹⁴. In the pre-hypertensive phase, SHR show a higher abundance of NHE3 in the
281 body of the microvilli, where it associates with DPP4 and lower pS552-NHE3 levels.
282 Once hypertension is established, however, SHR this association is reduced and
283 pS552-NHE3 is higher, diminishing PT sodium reabsorption, and contributing to
284 pressure-natriuresis¹⁴. Similarly, DPP4is attenuate BP in pre-hypertensive SHR but
285 lose their effectiveness once hypertension is established²⁵. A similar pattern is seen in
286 Ang II-induced hypertension, where DPP4is fail to lower BP after hypertension onset²⁷.
287 These observations suggest that one plausible explanation for the conflicting data on
288 the effects of DPP4is on BP is that their ability to enhance pS552-NHE3 levels and
289 inhibit NHE3 activity is already maximized in established hypertension, rendering further
290 intervention ineffective. Furthermore, as DPP4is and RAS blockers share overlapping
291 mechanisms^{46,47}, their combined use in hypertension therapy warrants further
292 investigation, as it may amplify adverse effects.

293 Accumulating evidence from our group and others highlights a crosstalk between
294 the signaling pathways activated by Ang II/AT1R and DPP4⁴⁰. In cultured PT cells,
295 supraphysiological concentrations of Ang II enhance DPP4 activity in an ERK 1/2-
296 dependent manner through AT1R activation⁴⁸. Conversely, DPP4is prevent Ang
297 II/AT1R-mediated activation of ERK 1/2. Consistent with these observations, we found
298 that the Ang II-induced increase in DPP4 activity is confined to PT DPP4, as kidney
299 DPP4 activity remained unchanged in *Dpp4*^{ΔPT} mice following Ang II treatment.
300 Interestingly, renal Ang II concentrations were upregulated in *Dpp4*^{ΔPT} and *Dpp4*^{-/-} (see

301 Supplemental Figure S10), potentially suggesting a compensatory mechanism in
302 response to impaired signaling. Importantly, we have previously shown that the
303 interaction between Ang II/AT1R and DPP4 is pivotal in the pathophysiology of kidney
304 diseases, with DPP4 inhibition preventing glomerular and tubulointerstitial injury,
305 proteinuria, oxidative stress, inflammation, and fibrosis^{24,48-50} processes that are at least
306 partially driven by Ang II/AT1R signaling. Our current findings expand the understanding
307 of the Ang II/AT1R-DPP4 crosstalk, suggesting that it plays a critical role not only in
308 kidney disease pathophysiology but also in proximal tubular function.

309 In summary, our findings suggest that PT DPP4 exerts an anti-natriuretic effect
310 by tonically stimulating NHE3 through signaling pathways that prevent phosphorylation
311 of serine 552, a key residue associated with the inhibition of PT NHE3-mediated sodium
312 reabsorption. In the absence of DPP4, these regulatory mechanisms are altered,
313 leading to sustained upregulation of pS552-NHE3 levels and reduced BP sensitivity to
314 Ang II, likely due to an enhanced pressure-natriuresis response. Further studies are
315 needed to identify the signaling pathways activated by DPP4 under physiological
316 conditions, as well as their potential impact on NHE3 regulation and other proximal
317 tubular functions.

318

319 **SOURCES OF FUNDING**

320 This work was supported by grant 2021/14534-3 from the São Paulo Research
321 Foundation (FAPESP) and the National Council for Scientific and Technological
322 Development (CNPq 307156/2018-4) to ACC Girardi and NIH/NIDDK-5K08DK115886
323 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-

324 National Institutes of Health (NIH) to R Nistala. F Martins was a recipient of a Doctorate
325 scholarship (grant 2019/11944-6) and a Research Fellowship Abroad (BPE) (grant
326 2022/12282-0) from São Paulo Research Foundation (FAPESP).

327 **DISCLOSURES**

328 None.

329 **SUPPLEMENTAL MATERIAL**

330 Supplemental Methods

331 Supplementary Tables S1-S2

332 Figures S1–S17

333

334 **REFERENCES**

- 335 1. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside:
336 an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. *Crit Rev*
337 *Clin Lab Sci*. 2003;40:209-294. doi: 10.1080/713609354
- 338 2. Kenny AJ, Booth AG, George SG, Ingram J, Kershaw D, Wood EJ, Young AR. Dipeptidyl peptidase
339 IV, a kidney brush-border serine peptidase. *Biochem J*. 1976;157:169-182.
- 340 3. Girardi ACC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na⁺-H⁺ Exchanger
341 Isoform NHE3 and Dipeptidyl Peptidase IV in the Renal Proximal Tubule. *Journal of Biological*
342 *Chemistry*. 2001;276:46671-46677. doi: 10.1074/jbc.M106897200
- 343 4. Dekan G, Miettinen A, Schnabel E, Farquhar MG. Binding of monoclonal antibodies to
344 glomerular endothelium, slit membranes, and epithelium after in vivo injection. Localization of
345 antigens and bound IgGs by immunoelectron microscopy. *Am J Pathol*. 1990;137:913-927.
- 346 5. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine
347 deaminase with a T cell activation antigen, CD26. *Science*. 1993;261:466-469. doi:
348 10.1126/science.8101391
- 349 6. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H,
350 Dang NH, Morimoto C. CD26 up-regulates expression of CD86 on antigen-presenting cells by
351 means of caveolin-1. *Proc Natl Acad Sci U S A*. 2004;101:14186-14191. doi:
352 10.1073/pnas.0405266101
- 353 7. Hanski C, Huhle T, Gossrau R, Reutter W. Direct evidence for the binding of rat liver DPP IV to
354 collagen in vitro. *Exp Cell Res*. 1988;178:64-72. doi: 10.1016/0014-4827(88)90378-3
- 355 8. Löster K, Zeilinger K, Schuppan D, Reutter W. The cysteine-rich region of dipeptidyl peptidase IV
356 (CD 26) is the collagen-binding site. *Biochem Biophys Res Commun*. 1995;217:341-348. doi:
357 10.1006/bbrc.1995.2782

- 358 9. Gonzalez-Gronow M, Misra UK, Gawdi G, Pizzo SV. Association of plasminogen with dipeptidyl
359 peptidase IV and Na⁺/H⁺ exchanger isoform NHE3 regulates invasion of human 1-LN prostate
360 tumor cells. *J Biol Chem*. 2005;280:27173-27178. doi: 10.1074/jbc.M500383200
- 361 10. Vallon V, Schwark JR, Richter K, Hropot M. Role of Na⁽⁺⁾/H⁽⁺⁾ exchanger NHE3 in nephron
362 function: micropuncture studies with S3226, an inhibitor of NHE3. *Am J Physiol Renal Physiol*.
363 2000;278:F375-379.
- 364 11. Schultheis PJ, Clarke LL, Meneton P, Miller ML, Soleimani M, Gawenis LR, Riddle TM, Duffy JJ,
365 Doetschman T, Wang T, et al. Renal and intestinal absorptive defects in mice lacking the NHE3
366 Na⁺/H⁺ exchanger. *Nat Genet*. 1998;19:282-285. doi: 10.1038/969
- 367 12. Li XC, Soleimani M, Zhu D, Rubera I, Tauc M, Zheng X, Zhang J, Chen X, Zhuo JL. Proximal Tubule-
368 Specific Deletion of the NHE3 (Na⁺/H⁺ Exchanger 3) Promotes the Pressure-Natriuresis Response
369 and Lowers Blood Pressure in Mice. *Hypertension*. 2018;72:1328-1336. doi:
370 10.1161/HYPERTENSIONAHA.118.10884
- 371 13. Li XC, Zhu D, Chen X, Zheng X, Zhao C, Zhang J, Soleimani M, Rubera I, Tauc M, Zhou X, et al.
372 Proximal Tubule-Specific Deletion of the NHE3 (Na⁺/H⁺ Exchanger 3) in the Kidney Attenuates
373 Ang II (Angiotensin II)-Induced Hypertension in Mice. *Hypertension*. 2019;74:526-535. doi:
374 10.1161/HYPERTENSIONAHA.119.13094
- 375 14. Crajinas RO, Lessa LMA, Carraro-Lacroix LR, Davel APC, Pacheco BPM, Rossoni LV, Malnic G,
376 Girardi ACC. Posttranslational mechanisms associated with reduced NHE3 activity in adult vs.
377 young prehypertensive SHR. *American Journal of Physiology-Renal Physiology*. 2010;299:F872-
378 F881. doi: 10.1152/ajprenal.00654.2009
- 379 15. Panico C, Luo Z, Damiano S, Artigiano F, Gill P, Welch WJ. Renal proximal tubular reabsorption is
380 reduced in adult spontaneously hypertensive rats: roles of superoxide and Na⁺/H⁺ exchanger 3.
381 *Hypertension*. 2009;54:1291-1297. doi: 10.1161/HYPERTENSIONAHA.109.134783
- 382 16. Thomas D, Harris PJ, Morgan TO. Age-related changes in angiotensin II-stimulated proximal
383 tubule fluid reabsorption in the spontaneously hypertensive rat. *J Hypertens Suppl*. 1988;6:S449-
384 451. doi: 10.1097/00004872-198812040-00141
- 385 17. McDonough AA. ISN Forefronts Symposium 2015: Maintaining Balance Under Pressure-
386 Hypertension and the Proximal Tubule. *Kidney Int Rep*. 2016;1:166-176. doi:
387 10.1016/j.ekir.2016.06.008
- 388 18. Zheng K, Layton AT. Predicting Sex Differences in the Effects of Diuretics in Renal Epithelial
389 Transport during Angiotensin II-induced Hypertension. *Am J Physiol Renal Physiol*. 2024. doi:
390 10.1152/ajprenal.00398.2023
- 391 19. Magyar CE, Zhang Y, Holstein-Rathlou NH, McDonough AA. Proximal tubule Na transporter
392 responses are the same during acute and chronic hypertension. *Am J Physiol Renal Physiol*.
393 2000;279:F358-369. doi: 10.1152/ajprenal.2000.279.2.F358
- 394 20. Girardi ACC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating
395 activity of Na⁺/H⁺ exchanger isoform NHE3 in proximal tubule cells. *American Journal of*
396 *Physiology - Cell Physiology*. 2004;287:C1238-C1245. doi: 10.1152/ajpcell.00186.2004
- 397 21. Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, Drucker DJ, Vallon V. Natriuretic
398 effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor
399 and preserved in obese type 2 diabetic mice. *Am J Physiol Renal Physiol*. 2012;303:F963-971.
400 doi: 10.1152/ajprenal.00259.2012
- 401 22. Girardi ACC, Fukuda LE, Rossoni LV, Malnic G, Reboucas NA. Dipeptidyl peptidase IV inhibition
402 downregulates Na⁽⁺⁾-H⁽⁺⁾ exchanger NHE3 in rat renal proximal tubule. *American Journal of*
403 *Physiology-Renal Physiology*. 2008;294:F414-F422. doi: 10.1152/ajprenal.00174.2007
- 404 23. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of
405 sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with

- 406 mild to moderate hypertension. *J Clin Pharmacol.* 2008;48:592-598. doi:
407 10.1177/0091270008316885
- 408 24. Benetti A, Martins FL, Sene LB, Shimizu MHM, Seguro AC, Luchi WM, Girardi ACC. Urinary DPP4
409 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin
410 and podocin expression in experimental CKD. *Am J Physiol Renal Physiol.* 2021;320:F285-F296.
411 doi: 10.1152/ajprenal.00288.2020
- 412 25. Pacheco BPM, Crajoinas RO, Couto GK, Davel APC, Lessa LM, Rossoni LV, Girardi ACC. Dipeptidyl
413 peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive
414 rats. *Journal of Hypertension.* 2011;29:520-528. doi: 10.1097/HJH.0b013e328341939d
- 415 26. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial
416 blood pressure is context dependent. *Hypertension.* 2015;65:238-249. doi:
417 10.1161/HYPERTENSIONAHA.114.04631
- 418 27. Nistala R, Meuth AI, Smith C, An J, Habibi J, Hayden MR, Johnson M, Aroor A, Whaley-Connell A,
419 Sowers JR, et al. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury
420 in male mice. *Am J Physiol Renal Physiol.* 2021;320:F505-F517. doi:
421 10.1152/ajprenal.00565.2020
- 422 28. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T,
423 Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice
424 lacking CD26. *Proc Natl Acad Sci U S A.* 2000;97:6874-6879. doi: 10.1073/pnas.120069197
- 425 29. Rubera I, Poujeol C, Bertin G, Hasseine L, Counillon L, Poujeol P, Tauc M. Specific Cre/Lox
426 recombination in the mouse proximal tubule. *J Am Soc Nephrol.* 2004;15:2050-2056. doi:
427 10.1097/01.ASN.0000133023.89251.01
- 428 30. Castro PC, Santos-Rios TM, Martins FL, Crajoinas RO, Caetano MV, Lessa LMA, Luchi WM,
429 McCormick JA, Girardi ACC. Renal upregulation of NCC counteracts empagliflozin-mediated
430 NHE3 inhibition in normotensive but not in hypertensive male rats. *Am J Physiol Cell Physiol.*
431 2024. doi: 10.1152/ajpcell.00351.2023
- 432 31. Veiras LC, Girardi ACC, Curry J, Pei L, Ralph DL, Tran A, Castelo-Branco RC, Pastor-Soler N, Arranz
433 CT, Yu ASL, et al. Sexual Dimorphic Pattern of Renal Transporters and Electrolyte Homeostasis.
434 *Journal of the American Society of Nephrology.* 2017;28:3504-3517. doi:
435 10.1681/ASN.2017030295
- 436 32. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BPM, Lessa LMA, Malnic G, Girardi ACC.
437 Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-
438 like peptide-1. *American Journal of Physiology-Renal Physiology.* 2011;301:F355-F363. doi:
439 10.1152/ajprenal.00729.2010
- 440 33. Biemesderfer D, DeGray B, Aronson PS. Active (9.6 s) and inactive (21 s) oligomers of NHE3 in
441 microdomains of the renal brush border. *J Biol Chem.* 2001;276:10161-10167. doi:
442 10.1074/jbc.M008098200
- 443 34. Brasen JC, Burford JL, McDonough AA, Holstein-Rathlou NH, Peti-Peterdi J. Local pH domains
444 regulate NHE3-mediated Na⁺ reabsorption in the renal proximal tubule. *Am J Physiol Renal*
445 *Physiol.* 2014;307:F1249-1262. doi: 10.1152/ajprenal.00174.2014
- 446 35. Kocinsky HS, Girardi AC, Biemesderfer D, Nguyen T, Mentone S, Orłowski J, Aronson PS. Use of
447 phospho-specific antibodies to determine the phosphorylation of endogenous Na⁺/H⁺
448 exchanger NHE3 at PKA consensus sites. *Am J Physiol Renal Physiol.* 2005;289:F249-258. doi:
449 10.1152/ajprenal.00082.2004
- 450 36. Kurashima K, Yu FH, Cabado AG, Szabó EZ, Grinstein S, Orłowski J. Identification of sites required
451 for down-regulation of Na⁺/H⁺ exchanger NHE3 activity by cAMP-dependent protein kinase.
452 phosphorylation-dependent and -independent mechanisms. *J Biol Chem.* 1997;272:28672-
453 28679. doi: 10.1074/jbc.272.45.28672

- 454 37. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin
455 hormone glucagon-like peptide 1. *Pflugers Arch.* 1998;435:583-594. doi:
456 10.1007/s004240050558
- 457 38. Girardi A, Aronson P. Mechanism of association of NHE3 with DPPIV in renal proximal tubule.
458 *Journal of the American Society of Nephrology.* 2003;14:540A.
- 459 39. Crajoinas RO, Polidoro JZ, Girardi ACC. The potential role of myosin motor proteins in mediating
460 the subcellular distribution of NHE3 in the renal proximal tubule. *Am J Physiol Renal Physiol.*
461 2019. doi: 10.1152/ajprenal.00577.2018
- 462 40. Chiang SM, Ueng KC, Yang YS. Gender differences in variables associated with dipeptidyl
463 peptidase 4 genetic polymorphisms in coronary artery disease. *Adv Clin Exp Med.* 2020;29:1181-
464 1186. doi: 10.17219/acem/126291
- 465 41. Stubbe HC, Dahlke C, Rotheneder K, Stirner R, Roeder J, Conca R, Seybold U, Bogner J, Addo MM,
466 Draenert R. Integration of microarray data and literature mining identifies a sex bias in
467 DPP4+CD4+ T cells in HIV-1 infection. *PLoS One.* 2020;15:e0239399. doi:
468 10.1371/journal.pone.0239399
- 469 42. Pacheco-Alvarez D, Cristóbal PS, Meade P, Moreno E, Vazquez N, Muñoz E, Díaz A, Juárez ME,
470 Giménez I, Gamba G. The Na⁺:Cl⁻ cotransporter is activated and phosphorylated at the amino-
471 terminal domain upon intracellular chloride depletion. *J Biol Chem.* 2006;281:28755-28763. doi:
472 10.1074/jbc.M603773200
- 473 43. Stanton BA, Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery.
474 II. Na⁺ and K⁺ transport. *Am J Physiol.* 1988;255:F1269-1275. doi:
475 10.1152/ajprenal.1988.255.6.F1269
- 476 44. Pontes RB, Nishi EE, Crajoinas RO, Milanez MIO, Girardi ACC, Campos RR, Bergamaschi CT.
477 Relative Contribution of Blood Pressure and Renal Sympathetic Nerve Activity to Proximal
478 Tubular Sodium Reabsorption via NHE3 Activity. *Int J Mol Sci.* 2022;24. doi:
479 10.3390/ijms24010349
- 480 45. Luchi WM, Crajoinas RO, Martins FL, Castro PC, Venturini G, Seguro AC, Girardi ACC. High blood
481 pressure induced by vitamin D deficiency is associated with renal overexpression and
482 hyperphosphorylation of Na⁺-K⁺-2Cl⁻ cotransporter type 2. *J Hypertens.* 2020;Publish Ahead of
483 Print. doi: 10.1097/HJH.0000000000002745
- 484 46. Arruda-Junior DF, Salles TA, Martins FL, Antonio EL, Tucci PJF, Gowdak LHW, Tavares CAM,
485 Girardi AC. Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin
486 system in heart failure. *Life Sci.* 2022;305:120757. doi: 10.1016/j.lfs.2022.120757
- 487 47. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use
488 associated with increased risk of ACE inhibitor-associated angioedema. *Hypertension.*
489 2009;54:516-523. doi: 10.1161/HYPERTENSIONAHA.109.134197
- 490 48. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, Hayden MR, Johnson MS,
491 Salam M, Whaley-Connell A, et al. Dipeptidylpeptidase inhibition is associated with
492 improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese
493 rats. *Endocrinology.* 2013;154:2501-2513. doi: 10.1210/en.2013-1096
- 494 49. Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, Knight W, Hancock T, Klein T,
495 DeMarco VG, et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the
496 Zucker obese rat. *Obesity (Silver Spring).* 2014;22:2172-2179. doi: 10.1002/oby.20833
- 497 50. Nistala R, Habibi J, Lastra G, Manrique C, Aroor AR, Hayden MR, Garro M, Meuth A, Johnson M,
498 Whaley-Connell A, et al. Prevention of obesity-induced renal injury in male mice by DPP4
499 inhibition. *Endocrinology.* 2014;155:2266-2276. doi: 10.1210/en.2013-1920

501 **FIGURE LEGENDS**

502

503 **Figure 1 – Phenotypic characterization of *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice.** DPP4 protein
504 abundance was evaluated by immunoblotting using equivalent amounts of 10 μg of
505 renal homogenate samples from mice with either **(A)** PT-specific (*Dpp4*^{ΔPT}) or **(B)** global
506 (*Dpp4*^{-/-}) *Dpp4* deletion and their respective controls. Each dot represents the % of
507 DPP4 expression relative to male CTRL or WT per animal. Representative images of
508 the immunostaining of kidney sections for SGLT2, a PT marker, and DPP4 in **(C)**
509 *Dpp4*^{ΔPT} and **(D)** *Dpp4*^{-/-} mice. Renal DPP4 activity assessed by fluorimetry in renal
510 homogenates from **(E)** *Dpp4*^{ΔPT} and **(F)** *Dpp4*^{-/-} mice. Each dot represents the % of
511 DPP4 activity relative to male CTRL or WT per animal. Bars represent mean ± SEM.
512 **P < 0.01 and ****P < 0.0001.

513

514 **Figure 2 – Blood pressure and acute natriuretic and diuretic responses in male**
515 **and female *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice.** Systolic blood pressure (SBP) was measured
516 by tail-cuff plethysmography in male and female **(A)** *Dpp4*^{ΔPT} and **(B)** *Dpp4*^{-/-} mice.
517 Acute renal natriuretic and diuretic responses were evaluated after a saline challenge.
518 Results expressed as **(C-D)** % of fluid load and **(E-F)** % sodium load excreted within 5
519 hours. Each dot represents individual measurements. Bars represent mean ± SEM. *P <
520 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.

521

522 **Figure 3 – Effect of *Dpp4* deletion on kidney NHE3 (Na⁺/H⁺ exchanger isoform 3)**
523 **phosphorylation in male and female *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice.** Levels of

524 phosphorylated (pS552-NHE3) and total NHE3 were determined by immunoblotting in
525 kidney homogenates from **(A)** *Dpp4*^{ΔPT} and **(B)** *Dpp4*^{-/-} mice. Each dot represents the %
526 of pS552-NHE3/NHE3 relative to male CTRL or WT per animal. Bars represent mean ±
527 SEM. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.

528

529 **Figure 4 – Effect of acute Ang II administration on the renal DPP4 activity of male**
530 **and female mice.** Renal DPP4 activity assessed by fluorimetry in renal homogenates
531 from male and female **(A-B)** *Dpp4*^{ΔPT} and **(C-D)** *Dpp4*^{-/-} mice. Each dot represents the
532 % of DPP4 activity relative to CTRL or WT per animal. Bars represent mean ± SEM.
533 ****P < 0.0001.


534

535 **Figure 5 – Effect of a pressor dose of Ang II on blood pressure in *Dpp4*^{ΔPT} and**
536 ***Dpp4*^{-/-} mice.** Systolic blood pressure (SBP) was measured by tail-cuff
537 plethysmography before and after Ang II administration in **(A-B)** male and female
538 *Dpp4*^{ΔPT} and **(C-D)** *Dpp4*^{-/-} mice. Each dot represents the ΔSBP change per animal.
539 Bars represent mean ± SEM. *P < 0.05; **P < 0.01 and ****P < 0.0001.


540

541 **Figure 6 – Influence of acute Ang II-induced blood pressure rise on NHE3**
542 **phosphorylation in the kidneys of *Dpp4*^{ΔPT} and *Dpp4*^{-/-} mice.** Levels of
543 phosphorylated (pS552-NHE3) and total NHE3 were determined by immunoblotting in
544 kidney homogenates from *Dpp4*^{ΔPT} **(A-B)** and *Dpp4*^{-/-} **(C-D)** mice. Each dot represents
545 the % of pS552-NHE3/NHE3 relative to CTRL or WT per animal. Bars represent mean ±
546 SEM. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.


A




B




C




D











E












F




A**B****C****D****E****F**

A**B**


A**B****C****D****E**

A**B****C****D**


A



B



C



D

